Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2a single arm study to evaluate the effect of TCN -202 (human anti-cytomegalovirus monoclonal antibody) on CMV infection in CMV (cytomegalovirus) seronegative recipients of kidney allografts from CMV seropositive donors

Trial Profile

A phase 2a single arm study to evaluate the effect of TCN -202 (human anti-cytomegalovirus monoclonal antibody) on CMV infection in CMV (cytomegalovirus) seronegative recipients of kidney allografts from CMV seropositive donors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TCN 202 (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Theraclone Sciences
  • Most Recent Events

    • 13 Dec 2013 Initiation date changed from 10 September 2013 to 27 August 2013, as per Brazilian Clinical Trials Registry record
    • 11 Dec 2013 As per Brazilian Clinical Trials Registry record, the expected date of last enrollment is 31 May 2014
    • 11 Dec 2013 As per the Brazilian Clinical Trials Registry record; the primary endpoint has been changed form viral load to proportion of patients receiving the CMV infection. The dose has been changed from 1 mg/ kg to 15 mg/kg.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top